Tiziana Life Sciences PLC Director/PDMR Dealing (3649Z)

TIDMTILS

RNS Number : 3649Z

Tiziana Life Sciences PLC

21 May 2021

Tiziana Life Science plc

PDMR Dealing

London, New York, 21 May 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 ordinary shares of 3p each in the market at a price of 71p per share.

The acquisition takes Mr Cerrone's interests from 34.070% to 34.075% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

 
 1.    Details of PDMR / person closely associated 
 a)    Name                Gabriele Cerrone 
      ------------------  ------------------------------------------------- 
 2.    Reason for the notification 
      --------------------------------------------------------------------- 
 a)    Position            Executive Chairman 
        / status 
      ------------------  ------------------------------------------------- 
 b)    Initial             Initial notification 
        notification 
        /amendment 
      ------------------  ------------------------------------------------- 
 3.    Details of the issuer 
      --------------------------------------------------------------------- 
 a)    Name                Tiziana Life Sciences plc 
      ------------------  ------------------------------------------------- 
 b)    LEI                 213800CED47HI8PIOB36 
      ------------------  ------------------------------------------------- 
 4.    Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------- 
 a)    Description         Ordinary Shares of 3p each 
        of the 
        financial 
        instrument 
      ------------------  ------------------------------------------------- 
 b)    Identification      ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 
        code of 
        the Financial 
        Instrument 
      ------------------  ------------------------------------------------- 
 c)    Nature              Market Purchase 
        of the 
        transaction 
      ------------------  ------------------------------------------------- 
       Price(s)            71p 
 d)     and volume(s)       10,000 
      ------------------  ------------------------------------------------- 
 f)    Date of             20 May 2021 
        the transaction 
      ------------------  ------------------------------------------------- 
 g)    Place of            XLON 
        the transaction 
      ------------------  ------------------------------------------------- 
 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation, and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)

Gabriele Cerrone, Chairman and founder [phone]

U.S. Investor Relations Contact:

RedChip Companies, Inc.

Dave Gentry 001 - 407-491-4498 [e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHURORRAKUVUUR

(END) Dow Jones Newswires

May 21, 2021 02:00 ET (06:00 GMT)